A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 600
- 试验地点
- 1
- 主要终点
- Response rate
研究概览
简要总结
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
详细描述
The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows.
- Registration after informed consent.
- Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood
- Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood
- Regular monitoring disease status and update of survival status
- Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
- •Patients requiring systemic chemotherapy with curative intent
- •Written informed consent
排除标准
- •Myeloid malignancy
- •Multiple myeloma
- •Patients do not require systemic chemotherapy with curative intent
研究组 & 干预措施
Lymphoma
Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.
干预措施: Chemotherapy (Drug)
结局指标
主要结局
Response rate
时间窗: 3 months after chemotherapy
response to chemotherapy
次要结局
- Biomarker(3 year)
- Progression-free survival(3 year)
- Overall survival(3 year)